Dyadic International (DYAI) Small-Cap Virtual Conference summary

Strategic transformation and market focus

• Shifted from a platform-based, R&D-focused organization to a product-driven, revenue-focused company targeting high-growth, non-therapeutic markets.

• Rebranded and restructured to prioritize faster, more reliable revenue streams in life sciences, food, nutrition, and bioindustrial sectors.

• Platforms C1 and Dapibus enable high-yield, animal-free recombinant protein production at scale, addressing market demand for sustainable, non-animal solutions.

• Biopharmaceutical programs moved to a legacy department, focusing resources on non-therapeutic commercialization.

• Partnerships and commercial engines are validated and generating initial revenues across all verticals.

Product pipeline and commercialization

• Targeting $25 billion in addressable markets, with active product launches and partnerships in cell culture media, DNA/RNA reagents, and alternative proteins.

• Key products include recombinant albumin, transferrin, growth factors, DNase I, and alpha-lactalbumin, with launches and initial sales expected between 2025 and 2027.

• Partnerships with Proliant, Enzymes, and Fermbox Bio are driving revenue and market penetration in life sciences, food/nutrition, and bioindustrial segments.

• Multiple monetization strategies: licensing, strategic partnerships, and direct product sales, enabling recurring revenues and shorter time to market.

• Initial revenues from new products and partnerships are already being realized, with recurring revenues expected within 15-18 months of product launch.

Financial outlook and growth trajectory

• Maintains a low annual burn rate of $4–5 million, with a forecast to achieve cash flow positivity by the end of 2026.

• Revenue ramp driven by product launches, licensing, and partnerships, especially in cell culture media and alternative proteins.

• Expects profitability within three years, with significant growth potential as additional products and markets are layered in.

• Biopharmaceutical legacy programs provide non-dilutive funding and strategic validation but are not the primary focus for near-term growth.

• Active expansion of the product pipeline and partnerships to accelerate revenue in 2026 and 2027.